Galera to Present at Three Upcoming Investor Conferences in September
September 07 2021 - 7:00AM
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage
biopharmaceutical company focused on developing and commercializing
a pipeline of novel, proprietary therapeutics that have the
potential to transform radiotherapy in cancer, today announced that
Mel Sorensen, M.D., President and Chief Executive Officer, will
present at three upcoming virtual investor conferences in
September.
Presentation Details:
Event: H.C. Wainwright 23rd Annual
Global Investment ConferenceDate: Monday,
September 13, 2021 Time: On-demand beginning at
7:00 a.m. ET
Event: Oppenheimer Fall Healthcare
Life Sciences & MedTech SummitDate: Tuesday,
September 21, 2021 Time: 11:35 a.m. ET
Event: Cantor Fitzgerald Global
Healthcare ConferenceDate: Wednesday, September
29, 2021 Time: 10:00 a.m. ET
Live webcasts from the three presentations will be
accessible from the Investors page of Galera’s website,
investors.galeratx.com. Following the events, archived webcasts
will be available on the Galera website for 30 days.
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage
biopharmaceutical company focused on developing and commercializing
a pipeline of novel, proprietary therapeutic candidates that have
the potential to transform radiotherapy in cancer. Galera’s lead
product candidate is avasopasem manganese (avasopasem, or GC4419),
a selective small molecule dismutase mimetic in late-stage
development to reduce the incidence and severity of
radiotherapy-induced severe oral mucositis (SOM) in patients with
head and neck cancer. Avasopasem is also in development for
radiotherapy-induced esophagitis in patients with lung cancer.
Avasopasem has been granted FDA Fast Track and Breakthrough Therapy
designations for the reduction of SOM induced by radiotherapy, with
or without systemic therapy. Galera’s second dismutase mimetic
product candidate, GC4711, is in clinical-stage development to
augment the anti-cancer efficacy of stereotactic body radiation
therapy in patients with non-small cell lung cancer and locally
advanced pancreatic cancer. Galera is headquartered in Malvern, PA.
For more information, please visit www.galeratx.com.
Investor Contacts:Christopher
DegnanGalera Therapeutics, Inc.610-725-1500cdegnan@galeratx.com
William WindhamSolebury
Trout646-378-2946wwindham@soleburytrout.com
Media Contact:Zara
LockshinSolebury Trout646-378-2960zlockshin@soleburytrout.com
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Sep 2023 to Sep 2024